Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2017

Open Access 01-12-2017 | Research

Clinical features and genotype-phenotype correlation analysis in patients with ATL1 mutations: A literature reanalysis

Authors: Guo-hua Zhao, Xiao-min Liu

Published in: Translational Neurodegeneration | Issue 1/2017

Login to get access

Abstract

Background

The hereditary spastic paraplegias (HSPs) are a group of clinically and genetically heterogeneous disorders. Approximately 10% of the autosomal dominant (AD) HSPs (ADHSPs) have the spastic paraplegia 3A (SPG3A) genotype which is caused by ATL1 gene mutations. Currently there are more than 60 reported ATL1 gene mutations and the genotype-phenotype correlation remains unclear. The study aims to investigate the genotype-phenotype correlation in SPG3A patients.

Methods

We performed a reanalysis of the clinical features and genotype-phenotype correlations in 51 reported studies exhibiting an ATL1 gene mutation.

Results

Most HSPs-SPG3A patients exhibited an early age at onset (AAO) of <10 years old, and showed an autosomal dominant pure spastic paraplegia. We found that 14% of the HSPs-SPG3A patients presented complicated phenotypes, with distal atrophy being the most common complicated symptom. The AAO of each mutation group was not statistically significant (P > 0.05). The mutational spectrum associated with ATL1 gene mutation is wide, and most mutations are missense mutations, but do not involve the functional motif of ATL1 gene encoded atlastin-1 protein.

Conclusions

Our findings indicate that there is no clear genotype-phenotype correlation in HSPs-SPG3A patients. We also find that exons 4, 7, 8 and 12 are mutation hotspots in ATL1 gene.
Appendix
Available only for authorised users
Literature
1.
Harding AE. Classification of the hereditary ataxia and paraplegias. Lancet. 1983;1(8334):1151–5.CrossRefPubMed
2.
Mc Dermott CJ, et al. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69(2):150–60.CrossRef
3.
4.
Hazan J, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23(3):296–303.CrossRefPubMed
5.
Tallaksen CM, Durr A, Brice A. Recent advances in hereditary spastic paraplegia. Current Opinion Neurol. 2001;14:457–63.CrossRef
6.
Zhao X, et al. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nat Genet. 2001;29(3):326–31.CrossRefPubMed
7.
Muglia M, Magariello A, Nicoletti G. Further evidence that SPG3A gene mutations cause autosomal dominant hereditary spastic paraplegia. Ann Neurol. 2002;51(6):794–5.CrossRefPubMed
8.
Tessa A, Casali C, Damiano M. SPG3A: An additional family carrying a new atlastin mutation. Neurology. 2002;59(12):2002–5.CrossRefPubMed
9.
Wilkinson PA, et al. SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia. J Neurol Sci. 2003;216(1):43–5.CrossRefPubMed
10.
Sartori E, et al. Infancy onset hereditary spastic paraplegia associated with a novel atlastin mutation. Neurology. 2003;61(4):580–1.CrossRefPubMed
11.
Sauter SM, et al. Novel mutations in the Atlastin gene (SPG3A) in families with autosomal dominant hereditary spastic paraplegia and evidence for late onset forms of HSP linked to the SPG3A locus. Hum Mutat. 2004;23(1):98.CrossRefPubMed
12.
D’Amico A, et al. Incomplete penetrance in an SPG3A-linked family with a new mutation in the atlastin gene. Neurology. 2004;62(11):2138–9.CrossRefPubMed
13.
Abel A, et al. Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A. Neurogenetics. 2004;5(4):239–43.CrossRefPubMed
14.
Hedera P, et al. Novel mutation in the SPG3A gene in an African American family with an early onset of hereditary spastic paraplegia. Arch Neurol. 2004;61(10):1600–3.CrossRefPubMed
15.
Dürr A, et al. Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch Neurol. 2004;61(12):1867–72.CrossRefPubMed
16.
Scarano V, et al. The R495W mutation in SPG3A causes spastic paraplegia associated with axonal neuropathy. J Neurol. 2005;252(8):901–3.CrossRefPubMed
17.
Namekawa M, et al. SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years. Neurology. 2006;66(1):112–4.CrossRefPubMed
18.
Rainier S, et al. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. Arch Neurol. 2005;63(3):445–7.CrossRef
19.
Chen SQ, et al. Severe hereditary spastic paraplegia caused by a de novo SPG3A mutation. Sci China. 2005;51(15):1854–6. In Chinese.
20.
Matsui M, et al. A novel mutation in the SPG3A gene (atlastin) in hereditary spastic paraplegia. J Neurol. 2007;54(7):972–4.CrossRef
21.
Ivanova N, et al. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007;64(5):706–13.CrossRefPubMed
22.
Li XH, et al. A SPG3A mutation with a novel foot phenotype of hereditary spastic paraplegia in a Chinese Han family. Chin Med J (Engl). 2007;120(9):834–7.
23.
Meijer IA, et al. Characterization of a novel SPG3A deletion in a French-Canadian family. Ann Neurol. 2007;61(6):599–603.CrossRefPubMed
24.
Ming L. SPG3A-hereditary spastin paraplegia with genetic anticipation and incomplete penetrance. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007;24(1):15–8. In Chinese.PubMed
25.
Haberlová J, et al. Extending the clinical spectrum of SPG3A mutations to a very severe and very early complicated phenotype. J Neurol. 2008;255(6):927–8.CrossRefPubMed
26.
Loureiro JL, et al. Novel SPG3A and SPG4 mutations in dominant spastic paraplegia families. Acta Neurol Scand. 2009;119(2):113–8.CrossRefPubMed
27.
Svenstrup K, et al. Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia. J Neurol Sci. 2009;284(1–2):90–5.CrossRefPubMed
28.
Chan KY, et al. Hereditary spastic paraplegia: identification of an SPG3A gene mutation in a Chinese family. Hong Kong Med J. 2009;15(4):304–7.PubMed
29.
Smith BN, et al. Four novel SPG3A/atlastin mutations identified in autosomal dominant hereditary spastic paraplegia kindreds with intra-familial variability in age of onset and complex phenotype. Clin Genet. 2009;75(5):485–9.CrossRefPubMed
30.
Fusco C, et al. Hereditary spastic paraplegia and axonal motor neuropathy caused by a novel SPG3A de novo mutation. Brain Dev. 2010;32(7):592–4.CrossRefPubMed
31.
Kwon MJ, et al. Clinical and genetic analysis of a Korean family with hereditary spastic paraplegia type 3. Ann Clin Lab Sci. 2010;40(4):375–9.PubMed
32.
Alvarez V, et al. Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurol. 2010;10:89.CrossRefPubMedPubMedCentral
33.
de Leva MF, et al. Complex phenotype in an Italian family with a novel mutation in SPG3A. J Neurol. 2010;257(3):328–31.CrossRefPubMed
34.
Orlacchio A, et al. Late-onset hereditary spastic paraplegia with thin corpus callosum caused by a new SPG3A mutation. J Neurol. 2011;258(7):1361–3.CrossRefPubMed
35.
Al-Maawali A, et al. Hereditary spastic paraplegia associated with axonal neuropathy: a novel mutation of SPG3A in a large family. J Clin Neuromuscul Dis. 2011;12(3):143–6.CrossRefPubMed
36.
37.
Magariello A, et al. The p.Arg416Cys mutation in SPG3a gene associated with a pure form of spastic paraplegia. Muscle Nerve. 2012;45(6):919–20.CrossRefPubMed
38.
Fusco C, et al. Very early onset and severe complicated phenotype caused by a new spastic paraplegia 3A gene mutation. J Child Neurol. 2012;27(10):1348–50.CrossRefPubMed
39.
Sulek A, et al. Screening for the hereditary spastic paraplaegias SPG4 and SPG3A with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals. Neurol Sci. 2012;34(2):239–42.CrossRef
40.
Terada T, et al. SPG3A-linked hereditary spastic paraplegia associated with cerebral glucose hypometabolism. Ann Nucl Med. 2013;27(3):303–8.CrossRefPubMed
41.
de Bot ST, et al. ATL1 and REEP1 mutations in hereditary and sporadic upper motor neuron syndromes. J Neurol. 2013;260(3):869–75.CrossRefPubMed
42.
Varga RE, et al. Do not trust the pedigree: reduced and sex-dependent penetrance at a novel mutation hotspot in ATL1 blurs autosomal dominant inheritance of spastic paraplegia. Hum Mutat. 2013;34(6):860–3.CrossRefPubMed
43.
Loureiro JL, et al. Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey. JAMA Neurol. 2013;70(4):481–7.CrossRefPubMed
44.
Lu X, et al. Genetic analysis of SPG4 and SPG3A genes in a cohort of Chinese patients with hereditary spastic paraplegia. J Neurol Sci. 2014;347(1–2):368–71.CrossRefPubMed
45.
Luo Y, et al. Mutation and clinical characteristics of autosomal-dominant hereditary spastic paraplegias in China. Neurodegener Dis. 2014;14(4):176–83.CrossRefPubMed
46.
Shin JW, et al. Novel mutation in the ATL1 with autosomal dominant hereditary spastic paraplegia presented as dysautonomia. Auton Neurosci. 2014;185:141–3.CrossRefPubMed
47.
Yonekawa T, et al. Extremely severe complicated spastic paraplegia 3A with neonatal onset. Pediatr Neurol. 2014;51(5):726–9.CrossRefPubMed
48.
Khan TN, et al. Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation. Eur J Hum Genet. 2014;22(10):1180–4.CrossRefPubMedPubMedCentral
49.
Klein CJ, et al. Application of whole exome sequencing in undiagnosed inherited polyneuropathies. J Neurol Neurosurg Psychiatry. 2014;85(11):1265–72.CrossRefPubMed
50.
Ishiura H, et al. Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses. J Hum Genet. 2014;59(3):163–72.CrossRefPubMed
51.
Leonardi L, et al. De novo mutations in SPG3A: a challenge in differential diagnosis and genetic counselling. Neurol Sci. 2015;36(6):1063–4.CrossRefPubMed
52.
Park H, et al. Mutational spectrum of the SPAST and ATL1 genes in Korean patients with hereditary spastic paraplegia. J Neurol Sci. 2015;357(1–2):167–72.CrossRefPubMed
53.
Zhao N, et al. Mutation analysis of four Chinese families with pure hereditary spastic paraplegia: pseudo-X-linked dominant inheritance and male lethality due to a novel ATL1 mutation. Genet Mol Res. 2015;14(4):14690–7.CrossRefPubMed
54.
Elert-Dobkowska E, et al. Molecular spectrum of the SPAST, ATL1 and REEP1 gene mutations associated with the most common hereditary spastic paraplegias in a group of Polish patients. J Neurol Sci. 2015;359(1–2):35–9.CrossRefPubMed
55.
Polymeris AA, et al. A series of Greek children with pure hereditary spastic paraplegia: clinical features and genetic findings. J Neurol. 2016;263(8):1604–11.CrossRefPubMed
56.
Balicza P, et al. Genetic background of the hereditary spastic paraplegia phenotypes in Hungary-An analysis of 58 probands. J Neurol Sci. 2016;364(1):116–21.CrossRefPubMed
57.
Guelly C, et al. Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am J Hum Genet. 2011;88(1):99–105.CrossRefPubMedPubMedCentral
58.
Leonardis L, et al. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol. 2012;19(7):992–8.CrossRefPubMed
59.
Namekawa M, et al. A founder effect and mutational hotpots may contribute to the most frequent mutations in the SPG3A gene. Neurogenetics. 2016;7(2):131–2.CrossRef
60.
Sanderson CM, et al. Spastin and atlastin, two proteins mutated in autosomal-dominant hereditary spastic paraplegia, are binding partners. Hum Mol Genet. 2006;15(2):307–18.CrossRefPubMed
Metadata
Title
Clinical features and genotype-phenotype correlation analysis in patients with ATL1 mutations: A literature reanalysis
Authors
Guo-hua Zhao
Xiao-min Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2017
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-017-0079-3

Other articles of this Issue 1/2017

Translational Neurodegeneration 1/2017 Go to the issue

Research

Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration

Review

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Review

Music therapy is a potential intervention for cognition of Alzheimer’s Disease: a mini-review

Research

Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s disease

Research

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Review

Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?